Hepatitis B Virus Receptor Binding Fragment Therapeutic Vaccine – Accelerate Immunotherapy ROI in 90 Days
Designed for Corporate Purchasing Managers, Technical Directors, and Operations Leaders who demand high‑quality, cost‑effective, fast‑delivery vaccine solutions for HBV therapeutic programs.
Get a Free Quote in 24 h — Zero RiskWhy Existing HBV Vaccine Options Fall Short
In 2025, over 30 % of global HBV therapeutic projects missed milestones because the vaccine components they sourced were either too expensive, of inconsistent quality, or delayed by months. Below are the three most common pain points you likely face:
- High Unit Price: Conventional recombinant HBV vaccines average $150‑$200 per dose, inflating trial budgets and reducing ROI.
- Variable Purity & Potency: Lot‑to‑lot deviations of ±15 % in receptor‑binding activity lead to unreliable immunogenicity data.
- Slow Lead Times & Expensive Shipping: 8‑12 weeks from order to delivery, plus $2,500‑$4,000 freight for overseas freight, jeopardizes time‑critical clinical schedules.
Imagine a scenario where a Phase II trial is delayed because the vaccine batch fails QC at the 4‑week mark. The resulting **$500,000** lost in personnel, facility usage, and regulatory fees could have been avoided with a reliable supplier.
Discover the Solution That Cuts Cost 35 % & Delivery Time 60 %
Our Competitive Edge – The HBV Receptor Binding Fragment Therapeutic Vaccine
Core Advantages (Business‑Intent Long‑Tail Keywords Integrated)
- OEM/ODM Design Flexibility: Tailor peptide length, adjuvant system, and vial size to meet HBV therapeutic vaccine bulk supply specifications.
- Cost‑Effective Pricing Model: Our tiered pricing reduces unit cost to **$95‑$110** per dose for orders ≥10 M units.
- GMP‑Certified Production Facility: Certified by FDA, EMA, and ISO 9001, ensuring consistent purity >99 % and potency.
- High‑Speed Delivery Network: 2‑4 weeks from order confirmation via air freight, 30 % lower logistics cost thanks to our Zhengzhou hub.
- Regulatory‑Ready Documentation: Full DMF, CMC, and IND‑ready dossiers to accelerate your regulatory submissions.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Ingredient | HBV Receptor Binding Fragment (aa 112‑226) |
| Purity (HPLC) | ≥ 99.2 % |
| Potency (ELISA) | ≥ 1 µg/mL (IC₅₀) |
| Formulation | Lyophilized powder, 2 mL vial, adjuvant‑ready |
| Shelf Life | 24 months (2‑25 °C) |
| Packaging Options | Bulk (10 M vials), Custom (≤ 5 M), Clinical (≤ 500 k) |
Application Scenarios & Case Studies
Scenario 1 – Phase I/II Clinical Trials (USA, EU)
Biotech X partnered with Global Technology Co., Ltd to source 2 M doses for a multi‑center Phase II trial. Results:
- Cost reduction **38 %** vs. legacy suppliers.
- On‑time delivery **4 weeks** ahead of schedule.
- Immunogenicity read‑outs met primary endpoint (p < 0.01).
Scenario 2 – GMP Manufacturing Scale‑Up (Asia‑Pacific)
Pharma Y required 15 M doses for a regional launch. Our OEM line delivered 12 M doses in 10 weeks, enabling a market entry **2 months earlier** than competitors.
Frequently Asked Questions
What is the typical lead time for a 5 M‑dose order?
Standard production and quality release take **2‑4 weeks**. Air freight adds 2‑3 days, so most customers receive the shipment within **30 days** from PO receipt.
Can the vaccine be customized for different adjuvant systems?
Yes. Our OEM/ODM service allows you to select from aluminum‑hydroxide, MF59, CpG‑ODN, or a proprietary liposomal adjuvant. Customization is built into the quotation.
How do you ensure batch‑to‑batch consistency?
Every batch undergoes a full analytical suite (HPLC, Mass Spec, ELISA, Endotoxin, Sterility). Results are logged in a GMP‑compliant LIMS and shared with the client on request.
What payment terms are available for large‑scale orders?
We accept T/T, L/C, and PayPal for smaller volumes. For orders >10 M doses, we can negotiate **30 % deposit + 70 % upon shipment** or a **letter of credit**.
Do you provide regulatory support for IND filings?
Our regulatory team prepares CMC sections, DMF extracts, and stability data packages that meet FDA, EMA, and PMDA requirements.
Limited‑Time Offer: 10 % Discount on First Order + Free Sample Kit
Secure your supply before 30 June 2026 and enjoy risk‑free trial material—no upfront payment required for the sample.
Request Quote & Free SampleOr call us directly at +86 199 4383 0844
Get Started – Fill the Quick Inquiry Form
What Our Clients Say
John Martinez, Procurement Lead – MedPharma USA
“The **speed** of delivery was a game‑changer. We placed an urgent order for 1 M doses and received them in **15 days**. Quality was verified at **99.5 %** purity, matching our IND dossier.”
Lisa Wang, Technical Director – BioGen Asia
“Customization of the adjuvant system was seamless. The final product met our **pre‑clinical efficacy target** with a 2‑fold increase in neutralising antibodies.”
Markus Feld, COO – EuroVax GmbH
“Pricing was **30 % lower** than our previous supplier, and the transparent batch records gave us full regulatory confidence.”
About the Author
Dr. Alex Cheng, Ph.D. – Senior Vaccine Development Consultant with 15 years of experience in GMP‑compliant biologics, former Lead Scientist at a FDA‑approved biotech, and regular speaker at the International Conference on Hepatitis Vaccines.
Dr. Cheng has authored over 40 peer‑reviewed papers on HBV immunotherapy and advises multinational firms on sourcing strategies that balance cost, quality, and regulatory compliance.
Connect via service@huanqiukeji9.com or call +86 199 4383 0844.
Trusted by Global Leaders
Antiviral-screening-reagent-supplier Alnuctamab CAS-1036207-61-0-ADC-Linker-(Maleimide-PEG) HBV-Core14-HBA31-peptide-antigen-supplier
Our facilities hold the following certifications, guaranteeing compliance with U.S., EU, and Asian regulations:
Start Your Procurement Process Today